Claim OwnershipHealthcare Unfiltered
Subscribed: 63Played: 2,327
Subscribe
© 2025 Healthcare Unfiltered
Description
Healthcare Unfiltered is an honest, raw, timely podcast tackling any and all topics in healthcare that affect stakeholders. Dr. Chadi Nabhan uses his dynamic conversational skills to challenge his guests to address controversial and important topics. He also brings on world renowned experts to discuss clinical advances in medicine.
248 Episodes
Reverse
Dr. Anand Patel, DO, founder of LV8 Health, walks us through the philosophy and mechanics of concierge-style longevity medicine. He explains how LV8 applies Medicine 3.0, combining precision diagnostics (DEXA, VO₂ max, resting metabolic rate, advanced blood panels) with regenerative and geroprotective therapies, nutrition, fitness, and sleep optimization. You’ll hear how he translates data from wearables and diagnostics into bespoke plans, how he helps patients sustain behavior change, and ho...
Gavin MacBeath, CEO of TScan Therapeutics, takes us inside his journey from scientist to biotech leader and what it means to build and run a therapeutic development company at the cutting edge of immuno-oncology. He breaks down how TScan’s platform works to discover and match T-cell receptors (TCRs) with their antigens, and why TCR-T therapies may provide distinct benefits over CAR-T approaches, especially when tackling solid tumors. He also discusses which diseases are most likely to respond...
Dr. Sameer Keole, radiation oncologist at Mayo Clinic Arizona and president of ASTRO, joins the show to preview the upcoming ASTRO Annual Meeting and its key themes. He reflects on his presidential term, discussing accomplishments, lessons learned, and initiatives like his “defense to offense” vision and community outreach efforts. Dr. Keole also tackles hot-button topics in radiation oncology, including the evolving roles of proton therapy and artificial intelligence in patient care. Check o...
In this follow-up episode, Dr. Ed Livingston—renowned surgeon, educator, researcher, and former deputy editor at JAMA—returns to discuss the latest developments in his ongoing legal battle. He reflects on what has transpired in the three months since his last appearance, offering insights into the discovery process and the legal details shaping the case as it heads toward a July 2026 trial date.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan...
Dr. Douglas Flora, Executive Medical Director of Oncology Services at St. Elizabeth Healthcare Cancer Center and Editor-in-Chief of the journal AI in Precision Oncology, shares his pragmatic perspective on how AI is reshaping cancer care today and tomorrow. He discusses real-world applications such as FDA-approved pattern recognition tools in imaging and pathology, how AI may soon integrate with ctDNA to guide treatment decisions, and the clinical trials needed to advance this field. Dr. Flor...
Dr. Monique Diaz, Chief Medical Informatics Officer at CommonSpirit Health, unpacks the intersection of big data, clinical care, and healthcare innovation. She shares how informatics transforms resource allocation, patient engagement, and system efficiency—while offering a behind-the-scenes look at the daily responsibilities of a CMIO, from EMR coding to AI integration. Dr. Diaz also explores the evolving relationship between informatics and AI, and how future advancements hinge on ethical fr...
Dr. Sandy Scheinbaum, founder of the Functional Medicine Coaching Academy, joins the show to break down the principles of functional medicine—a patient-centered approach that integrates lifestyle, nutrition, psychology, and mind-body practices to address the root causes of illness. She shares how her academy trains coaches to guide individuals through sustainable behavior change, explains how mental and emotional states can directly impact physical symptoms, and discusses why functional medic...
Dr. Anthony DiGiorgio, a neurosurgeon at UCSF with a strong interest in healthcare policy, joins the show to unpack the complex and often misunderstood world of Medicaid. In a wide-ranging and nuanced discussion, he explores who qualifies for coverage, why most Medicaid spending goes to groups people don’t typically expect, and whether the system should be expanded or fundamentally reformed. Dr. DiGiorgio outlines his support for a robust safety net, emphasizing targeted subsidies over a gove...
Dr. Ed Livingston, renowned surgeon, educator, and researcher, who was a former deputy editor at JAMA, found himself out of a job after a JAMA podcast he hosted with Dr. Mitch Katz that discussed, among other items, structural racism as a contributor to the high mortality in minorities from COVID. This incident led to a series of lawsuits, some of which were highly publicized.Ed shares behind the scenes events, incidents, and what transpired in 2021, and how the AMA handled the situation. In ...
Ben Casavant, co-founder and CEO of Tasso, joins the show to discuss how he transformed the idea of patient-led blood collection into a reality through devices like Tasso+. He explains how Tasso’s self-collection kits—designed to be easy, virtually painless, and used anytime at home—solve the scalability issues of mobile phlebotomy while improving patient convenience, adherence, and access to care. Casavant also details the company’s growth journey, its FDA-cleared and CE-marked products, the...
Dr. Pallawi Torka of Memorial Sloan Kettering Cancer Center joins to share highlights from ASCO and EHA 2025 on the evolving landscape of B-cell lymphomas, including Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. She offers in-depth insights on the STARGLO study and its recent ODAC review, the POLARGO trial, a rare T-cell leukemia (T-LGL) study, and new data supporting nivolumab-AVD in frontline Hodgkin lymphoma. Additional discussion includes the inMIND tri...
Dr. Ben Derman of the University of Chicago Medicine joins the show to unpack major updates in multiple myeloma presented at ASCO and EHA 2025. He discusses the growing role of quadruple therapy across all patient populations and its implications for the future of autologous stem cell transplant, including insights from the MIDAS trial on MRD-guided transplant decisions. Additional highlights include MRD-negativity as a potential off-ramp for maintenance therapy, evolving data from frontline ...
Joe DePinto, MBA, Head of Cell, Gene & Advanced Therapies at McKesson, joins the show to discuss InspiroGene, McKesson’s end-to-end platform built to address the complex delivery, coordination, and commercialization needs of cell and gene therapies. He breaks down how InspiroGene integrates logistics, specialty pharmacy, patient support services, and real-time data tracking to close critical gaps in the CGT ecosystem—especially around why many eligible patients are still not being identif...
Chadi sits down with Lou Weisbach, entrepreneur and founder of the American Center for Cures, who shares his ambitious mission to raise $750 billion through an innovative public-private bond model to accelerate the prevention and cure of chronic diseases like cancer, Alzheimer's, diabetes, and Parkinson’s. Weisbach discusses how his model is designed to align incentives across government, industry, and research institutions, bridging political divides and pharmaceutical interests to focus on ...
Dr. Vivek Subbiah returns for another edition of Vivek’s Takes, offering his expert insights on the standout science from the 2025 ASCO Annual Meeting. He breaks down key developments including trispecific antibodies, the growing role of radioligand therapies, a new standard of care in small cell lung cancer, and paradigm-shifting data in adjuvant therapy for colorectal cancer. The discussion also highlights a long-term exercise intervention, adjuvant vaccine studies, ctDNA and MRD integratio...
Dena Marrinucci, PhD, co-founder and COO of Truvian Health, joins the show to discuss her mission to transform blood diagnostics through a point-of-care device that delivers rapid, actionable results. She shares the origin story of founding Truvian in 2015—coincidentally just weeks before the Theranos exposé—and reflects on navigating industry skepticism in the post-Theranos landscape. Marrinucci also outlines the company’s FDA submission process, the importance of empowering immediate patien...
Former FDA Commissioner Robert Califf returns to the show for an in-depth discussion on the integration of artificial intelligence into regulatory processes, including how AI is currently being used—and should be used—in drug and medical device approvals, the detection and review of fraudulent data, and clinical decision support systems. He also explores the boundaries between algorithmic automation and human judgment, emphasizing the importance of maintaining transparency, accountability, an...
Last week, Chadi and researchers explored the KETO-CTA study, which investigated the effects of the ketogenic diet on coronary plaque formation in Lean Mass Hyper-Responders (LMHR), or individuals who experience significant LDL cholesterol elevations on low-carb diets.This week, the other side of the conversation is presented.A leading cardiologist joins the show to critically examine the KETO-CTA study findings, questioning their clinical significance and broader applicability. What do these...
The ketogenic (keto) diet has surged in popularity, with many touting its weight loss and metabolic benefits. However, some individuals—particularly those following a low-carb, high-fat regimen—experience a significant rise in LDL cholesterol, a phenomenon now known as the Lean Mass Hyper-Responder (LMHR) phenotype. What does this mean for cardiovascular risk?In this episode, Chadi is joined by three of the lead investigators of the KETO-CTA study, recently published in The American Journal o...
Cardiologists Andrew Foy and Anish Koka return to the show for a deep and often contentious debate on one of the most pressing healthcare policy issues of our time: should the government negotiate drug prices? Using the Inflation Reduction Act (IRA) as a springboard, the conversation explores the underlying causes of inflated drug prices in the US, including the role of third-party payers, lack of transparency, and market distortions. The discussion also examines the global landscape—how othe...
Comments
Download from Google Play
Download from App Store
United States